Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Cyramza | Ramucirumab | Cancelled | ||||
Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete |